Table 2. Comparison of clinical characteristics between CMR and non-CMR CML patients.
| Clinical parameters | CMR (n = 51) median (range) | Non-CMR (n = 42) median (range) | P values |
|---|---|---|---|
| Age (yr) | 60.7 (28–85) | 59.5 (23–79) | 0.9446 |
| Sex,a female | 20 (39.2) | 15 (35.7) | 0.7287 |
| Weight (kg) | 60.3 (42–84) | 60.7 (45–102) | 0.3965 |
| Sokal risk (low/int./high) | 35/13/2 | 24/11/2 | 0.8688 |
| EUTOS risk (low/high) | 42/3 | 31/2 | 0.9140 |
| CML duration (mo) | 84.8 (22.4–229.4) | 77.3 (13.2–186.3) | 0.6576 |
| Prior IFN-αa | 8 (15.7) | 11 (26.2) | 0.2112 |
| Duration of IM treatment (mo) | 84.3 (22.4–116.6) | 77.1 (12.6–122.4) | 0.5036 |
| Actual daily IM dose (mg/d) | 400 (161.7–400) | 400 (66.7–400) | 0.9098 |
| Median time to CCyR (mo) | |||
| From diagnosis to CCyR | 6.6 (2.5–60.1) | 6.5 (1–103.3) | 0.8728 |
| From IM therapy to CCyR | 5.7 (2–46.5) | 4.8 (0.5–76.7) | 0.5431 |
| Median time to MMR (mo) | |||
| From diagnosis to MMR | 15.8 (4.4–185.6) | 30.5 (4.4–167.8) | 0.0937 |
| From IM therapy to MMR | 15.1 (3.2–76.1) | 19.6 (3.6–93.9) | 0.2429 |
| IM trough concentration (ng/ml) | 981.8 (336.3–2,687.7) | 1151.7 (124.4–2,624.1) | 0.5597 |
| BIM deletiona | 4 (7.8) | 7 (16.6) | 0.1898 |
BIM, BCL2L11 gene; CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.
a
Data presented as number (%) of patients.